PE20140909A1 - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT - Google Patents

COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT

Info

Publication number
PE20140909A1
PE20140909A1 PE2014000295A PE2014000295A PE20140909A1 PE 20140909 A1 PE20140909 A1 PE 20140909A1 PE 2014000295 A PE2014000295 A PE 2014000295A PE 2014000295 A PE2014000295 A PE 2014000295A PE 20140909 A1 PE20140909 A1 PE 20140909A1
Authority
PE
Peru
Prior art keywords
compounds
imidazo
pyridine
inhibitors
oxadiazol
Prior art date
Application number
PE2014000295A
Other languages
English (en)
Spanish (es)
Inventor
Valentina Molteni
Hank Michael James Petrassi
Xiaolin Li
Xiaodong Liu
Jon Loren
Juliet Nabakka
Bao Nguyen
Vince Yeh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20140909A1 publication Critical patent/PE20140909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2014000295A 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT PE20140909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
PE20140909A1 true PE20140909A1 (es) 2014-07-20

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000295A PE20140909A1 (es) 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT

Country Status (30)

Country Link
US (3) US8569283B2 (enExample)
EP (1) EP2751104B1 (enExample)
JP (1) JP6134319B2 (enExample)
KR (1) KR101962495B1 (enExample)
CN (1) CN103797011B (enExample)
AP (1) AP2014007493A0 (enExample)
AR (1) AR087753A1 (enExample)
AU (1) AU2012302042B2 (enExample)
BR (1) BR112014004560A2 (enExample)
CA (1) CA2845169C (enExample)
CL (1) CL2014000492A1 (enExample)
CO (1) CO6900141A2 (enExample)
CR (1) CR20140107A (enExample)
CU (1) CU20140024A7 (enExample)
EA (1) EA026152B1 (enExample)
ES (1) ES2761332T3 (enExample)
GT (1) GT201400034A (enExample)
IL (1) IL231227A0 (enExample)
MA (1) MA35460B1 (enExample)
MX (1) MX339937B (enExample)
PE (1) PE20140909A1 (enExample)
PH (1) PH12014500372A1 (enExample)
PL (1) PL2751104T3 (enExample)
PT (1) PT2751104T (enExample)
SG (1) SG2014014369A (enExample)
TN (1) TN2014000068A1 (enExample)
TW (1) TW201313717A (enExample)
UY (1) UY34301A (enExample)
WO (1) WO2013033167A1 (enExample)
ZA (1) ZA201401175B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2751104B1 (en) 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
ES2675720T3 (es) 2013-01-10 2018-07-12 Pulmokine, Inc. Inhibidores de quinasa no selectivos
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
MX2018015657A (es) 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclico como antibacterianos.
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11939320B2 (en) 2017-11-02 2024-03-26 Abbvie Inc. Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN114096538A (zh) * 2019-05-13 2022-02-25 诺华股份有限公司 N-(5-(5-((1r,2s)-2-氟环丙基)-1,2,4-噁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲酰胺的结晶型
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
KR20220115609A (ko) 2019-12-13 2022-08-17 니뽄 신야쿠 가부시키가이샤 Pdgf 수용체 키나아제 저해제로서의 화합물 및 조성물
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022016021A1 (en) 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
EP4247368A4 (en) * 2020-11-19 2024-10-23 Third Harmonic Bio, Inc. PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR THE PREPARATION AND USE THEREOF
EP4308239A1 (en) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN117440958A (zh) 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
MX2023010948A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
IL321144A (en) * 2022-11-30 2025-07-01 Blueprint Medicines Corp History of N-phenyl-pyrazolo[5,1-A]pyridine-3-carboxamide as wild-type C-KIT kinase inhibitors for the treatment of erectile dysfunction
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
CN120659784A (zh) * 2022-12-07 2025-09-16 第三谐波生物股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AP2470A (en) 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
JP2014525450A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物
WO2013033620A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP2751104B1 (en) 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
CA2845169C (en) 2022-04-19
US20140031333A1 (en) 2014-01-30
UY34301A (es) 2013-04-05
CR20140107A (es) 2014-05-02
AU2012302042B2 (en) 2016-03-31
SG2014014369A (en) 2014-09-26
KR101962495B1 (ko) 2019-03-26
GT201400034A (es) 2015-02-19
AU2012302042A1 (en) 2014-04-17
JP6134319B2 (ja) 2017-05-24
PH12014500372A1 (en) 2014-04-07
AP2014007493A0 (en) 2014-03-31
KR20140075692A (ko) 2014-06-19
BR112014004560A2 (pt) 2017-04-04
CL2014000492A1 (es) 2014-10-03
JP2014525448A (ja) 2014-09-29
US20140228347A1 (en) 2014-08-14
ES2761332T3 (es) 2020-05-19
CN103797011A (zh) 2014-05-14
CN103797011B (zh) 2016-03-30
IL231227A0 (en) 2014-04-30
US8754071B2 (en) 2014-06-17
TW201313717A (zh) 2013-04-01
PT2751104T (pt) 2019-12-16
ZA201401175B (en) 2015-01-28
MX339937B (es) 2016-06-17
US9023839B2 (en) 2015-05-05
CO6900141A2 (es) 2014-03-20
WO2013033167A1 (en) 2013-03-07
EA026152B1 (ru) 2017-03-31
EA201490545A1 (ru) 2014-07-30
US8569283B2 (en) 2013-10-29
AR087753A1 (es) 2014-04-16
TN2014000068A1 (en) 2015-07-01
US20130059832A1 (en) 2013-03-07
EP2751104B1 (en) 2019-09-25
MX2014002484A (es) 2014-11-25
MA35460B1 (fr) 2014-09-01
CU20140024A7 (es) 2014-04-24
PL2751104T3 (pl) 2020-04-30
CA2845169A1 (en) 2013-03-07
EP2751104A1 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
PE20140909A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
PE20141033A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
PE20141059A1 (es) Indazoles
PE20161475A1 (es) Pirazolopiridinas y pirazolopirimidinas
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
MX2012015120A (es) Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica.
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
EP4295841A3 (en) Sulfur (vi) fluoride compounds and their use in click-reaction
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20131464A1 (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
PE20140832A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR087870A1 (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
PE20120056A1 (es) Derivados de indol como antagonistas del receptor crth2
MX377581B (es) Compuestos antihelmínticos y composiciones y método de uso de los mismos.
PE20090041A1 (es) Derivados de triazol como inhibidores de la biosintesis de leucotrienos
BR112013009580A2 (pt) composto de fómrula (i), composição fungicida e método para controlar fungos fitopatogênicos
SG195106A1 (en) Trpv4 antagonists
PE20120494A1 (es) {5-[4-(3,3-DIMETIL-AZETIDINA-1-CARBONIL)-FENIL]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-2-IL}-AMIDA DE ACIDO CICLOPROPANOCARBOXILICO COMO INHIBIDOR DE LAS QUINASAS JANUS
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt

Legal Events

Date Code Title Description
FA Abandonment or withdrawal